Clinical Trial Update: Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a biweekly schedule of docetaxel and cisplatin in unresectable non-small cell lung cancer. The study is completed and results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Taxotere (docetaxel)

Snippet

Sponsor: Gyeongsang National University Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-03-03